You are here

cemiplimab

Sanofi says on track to regain solid position in cancer drugs

Reuters

Wed, 06/13/18 - 09:59 pm

molecular oncology

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Thu, 05/17/18 - 10:44 pm

Bristol-Myers Squibb

Jounce Therapeutics

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

Endpoints

Mon, 04/30/18 - 10:08 am

PD-1 inhibitors

Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete

SF Gate, CA

Sat, 02/10/18 - 09:47 am

PDL-1 inhibitors

Sanofi and Regeneron boost investment in cancer drug cemiplimab

Yahoo/Reuters

Mon, 01/8/18 - 09:43 am

On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo

Endpoints

Mon, 12/18/17 - 10:18 am

cervical cancer

head and neck cancer

Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

Motley Fool

Wed, 12/13/17 - 11:01 pm

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

Endpoints

Wed, 12/13/17 - 09:44 am

advanced cutaneous squamous cell carcinoma

Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance

Endpoints

Fri, 09/8/17 - 09:38 am

breakthrough status